• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧盟药品立法下噬菌体治疗的药用噬菌体调控路线图。

The Medicinal Phage-Regulatory Roadmap for Phage Therapy under EU Pharmaceutical Legislation.

机构信息

Chair of Public Law, Law School, Faculty of Law, Economics and Business, Martin-Luther-University Halle-Wittenberg, 06099 Halle an der Saale, Germany.

出版信息

Viruses. 2024 Mar 12;16(3):443. doi: 10.3390/v16030443.

DOI:10.3390/v16030443
PMID:38543808
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10974108/
Abstract

Bacteriophage therapy is a promising approach to treating bacterial infections. Research and development of bacteriophage therapy is intensifying due to the increase in antibiotic resistance and the faltering development of new antibiotics. Bacteriophage therapy uses bacteriophages (phages), i.e., prokaryotic viruses, to specifically target and kill pathogenic bacteria. The legal handling of this type of therapy raises several questions. These include whether phage therapeutics belong to a specially regulated class of medicinal products, and which legal framework should be followed with regard to the various technical ways in which phage therapeutics can be manufactured and administered. The article shows to which class of medicinal products phage therapeutics from wild type phages and from genetically modified (designer) phages do or do not belong. Furthermore, the article explains which legal framework is relevant for the manufacture and administration of phage therapeutics, which are manufactured in advance in a uniform, patient-independent manner, and for tailor-made patient-specific phage therapeutics. For the systematically coherent, successful translation of phage therapy, the article considers pharmaceutical law and related legal areas, such as genetic engineering law. Finally, the article shows how the planned legislative revisions of Directive 2001/83/EC and Regulation (EC) No 726/2004 may affect the legal future of phage therapy.

摘要

噬菌体疗法是治疗细菌感染的一种很有前途的方法。由于抗生素耐药性的增加和新抗生素的开发进展缓慢,噬菌体疗法的研究和开发正在加强。噬菌体疗法利用噬菌体(即噬菌体)特异性靶向并杀死病原菌。这种疗法的合法处理提出了几个问题。其中包括噬菌体疗法是否属于受特别监管的一类药物,以及在制造和管理噬菌体疗法的各种技术方法方面应遵循哪些法律框架。本文表明,来自野生型噬菌体和基因修饰(设计)噬菌体的噬菌体疗法属于或不属于哪种类别的药物。此外,本文还解释了制造和管理以统一、不依赖于患者的方式预先制造的噬菌体疗法以及针对特定患者的定制噬菌体疗法的相关法律框架。为了系统地、连贯地翻译噬菌体疗法,本文考虑了药品法和相关的法律领域,如基因工程法。最后,本文展示了指令 2001/83/EC 和法规 (EC) No 726/2004 的计划立法修订可能如何影响噬菌体疗法的法律前景。

相似文献

1
The Medicinal Phage-Regulatory Roadmap for Phage Therapy under EU Pharmaceutical Legislation.欧盟药品立法下噬菌体治疗的药用噬菌体调控路线图。
Viruses. 2024 Mar 12;16(3):443. doi: 10.3390/v16030443.
2
European regulatory aspects of phage therapy: magistral phage preparations.噬菌体疗法的欧洲监管方面:法定噬菌体制剂
Curr Opin Virol. 2022 Feb;52:24-29. doi: 10.1016/j.coviro.2021.11.005. Epub 2021 Nov 23.
3
A commentary on the development of engineered phage as therapeutics.关于工程噬菌体作为治疗手段发展的述评。
Drug Discov Today. 2021 Sep;26(9):2095-2098. doi: 10.1016/j.drudis.2021.06.013. Epub 2021 Jul 6.
4
Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?噬菌体疗法在耐药时代:我们的现状与未来走向
Clin Ther. 2020 Sep;42(9):1659-1680. doi: 10.1016/j.clinthera.2020.07.014. Epub 2020 Aug 31.
5
Bacteriophage therapy: an overview and the position of Italian Society of Infectious and Tropical Diseases.噬菌体疗法:概述及意大利传染病与热带病学会的立场
Infez Med. 2020 Sep 1;28(3):322-331.
6
The Magistral Phage.《御用药用噬菌体》
Viruses. 2018 Feb 6;10(2):64. doi: 10.3390/v10020064.
7
Formulation, stabilisation and encapsulation of bacteriophage for phage therapy.噬菌体的制剂学、稳定性和包封用于噬菌体治疗。
Adv Colloid Interface Sci. 2017 Nov;249:100-133. doi: 10.1016/j.cis.2017.05.014. Epub 2017 May 14.
8
Bacteriophage therapy against ESKAPE bacterial pathogens: Current status, strategies, challenges, and future scope.噬菌体疗法对抗 ESKAPE 细菌病原体:现状、策略、挑战和未来前景。
Microb Pathog. 2024 Jan;186:106467. doi: 10.1016/j.micpath.2023.106467. Epub 2023 Nov 28.
9
Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.药理认知噬菌体治疗:噬菌体抗细菌作用在动物和人体中的药效学和药代动力学障碍。
Microbiol Mol Biol Rev. 2019 Oct 30;83(4). doi: 10.1128/MMBR.00012-19. Print 2019 Nov 20.
10
Bacteriophage therapy for management of bacterial infections in veterinary practice: what was once old is new again.兽医实践中用于治疗细菌感染的噬菌体疗法:曾经的旧方法如今再度兴起。
N Z Vet J. 2018 Sep;66(5):229-235. doi: 10.1080/00480169.2018.1491348. Epub 2018 Jul 16.

引用本文的文献

1
Latest Advances in Inhalable Dry Powder Bacteriophage Therapy for Pulmonary Infections.吸入性干粉噬菌体治疗肺部感染的最新进展
Pharmaceutics. 2025 Aug 20;17(8):1077. doi: 10.3390/pharmaceutics17081077.
2
Bacteriophages against : challenges and opportunities.针对噬菌体的:挑战与机遇
Front Bioeng Biotechnol. 2025 Aug 7;13:1605263. doi: 10.3389/fbioe.2025.1605263. eCollection 2025.
3
Insight into Bacteriophage Therapy for Bacterial Infections and Cancer.对噬菌体疗法治疗细菌感染和癌症的见解。
Mol Biotechnol. 2025 Jul 9. doi: 10.1007/s12033-025-01466-w.
4
Current Applications and the Future of Phage Therapy for Periprosthetic Joint Infections.噬菌体疗法在人工关节感染中的当前应用及未来发展
Antibiotics (Basel). 2025 Jun 6;14(6):581. doi: 10.3390/antibiotics14060581.
5
Virological and Pharmaceutical Properties of Clinically Relevant Phages.临床相关噬菌体的病毒学和药学特性
Antibiotics (Basel). 2025 May 10;14(5):487. doi: 10.3390/antibiotics14050487.
6
Limitation of the Lytic Effect of Bacteriophages on and Other Enteric Bacterial Pathogens and Approaches to Overcome.噬菌体对[具体细菌名称未给出]及其他肠道细菌病原体的裂解作用局限性及克服方法
Int J Microbiol. 2025 May 15;2025:5936070. doi: 10.1155/ijm/5936070. eCollection 2025.
7
[Phage therapeutics and pharmaceutical legislation: classification, manufacture, placing on the market, and application].[噬菌体疗法与药品法规:分类、生产、上市及应用]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025 Jun;68(6):638-644. doi: 10.1007/s00103-025-04054-0. Epub 2025 May 9.
8
Harnessing the Activity of Lytic Bacteriophages to Foster the Sustainable Development Goals and the "One Health" Strategy.利用裂解性噬菌体的活性推动可持续发展目标和“同一个健康”战略。
Viruses. 2025 Apr 9;17(4):549. doi: 10.3390/v17040549.
9
The regulatory framework for microbiome-based therapies: insights into European regulatory developments.基于微生物组的疗法的监管框架:欧洲监管发展洞察
NPJ Biofilms Microbiomes. 2025 Mar 28;11(1):53. doi: 10.1038/s41522-025-00683-0.
10
Metagenomics as a Transformative Tool for Antibiotic Resistance Surveillance: Highlighting the Impact of Mobile Genetic Elements with a Focus on the Complex Role of Phages.宏基因组学作为抗生素耐药性监测的变革性工具:强调移动遗传元件的影响,重点关注噬菌体的复杂作用。
Antibiotics (Basel). 2025 Mar 12;14(3):296. doi: 10.3390/antibiotics14030296.

本文引用的文献

1
CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerations.用于应对抗生素耐药性危机的CRISPR噬菌体抗菌剂:科学、经济和监管方面的考量
J Law Biosci. 2024 Jan 26;11(1):lsad030. doi: 10.1093/jlb/lsad030. eCollection 2024 Jan-Jun.
2
Bacteriophage Production in Compliance with Regulatory Requirements.符合监管要求的噬菌体生产。
Methods Mol Biol. 2024;2734:89-115. doi: 10.1007/978-1-0716-3523-0_6.
3
Magistral Phage Preparations: Is This the Model for Everyone?顺势疗法制剂:这是每个人的理想模式吗?
Clin Infect Dis. 2023 Nov 2;77(Suppl 5):S360-S369. doi: 10.1093/cid/ciad481.
4
The Potential of Bacteriophage Therapy as an Alternative Treatment Approach for Antibiotic-Resistant Infections.噬菌体疗法作为一种替代治疗方法在治疗抗生素耐药感染中的潜力。
Med Princ Pract. 2024;33(1):1-9. doi: 10.1159/000534717. Epub 2023 Oct 25.
5
Regulations of phage therapy across the world.世界各地的噬菌体疗法监管
Front Microbiol. 2023 Oct 6;14:1250848. doi: 10.3389/fmicb.2023.1250848. eCollection 2023.
6
Bacteriophage Delivery Systems for Food Applications: Opportunities and Perspectives.用于食品应用的噬菌体输送系统:机遇与展望。
Viruses. 2023 May 29;15(6):1271. doi: 10.3390/v15061271.
7
Personalized aerosolised bacteriophage treatment of a chronic lung infection due to multidrug-resistant Pseudomonas aeruginosa.个体化雾化噬菌体治疗多重耐药铜绿假单胞菌引起的慢性肺部感染。
Nat Commun. 2023 Jun 27;14(1):3629. doi: 10.1038/s41467-023-39370-z.
8
Translating phage therapy into the clinic: Recent accomplishments but continuing challenges.将噬菌体疗法转化为临床应用:近期的成就与持续的挑战。
PLoS Biol. 2023 May 23;21(5):e3002119. doi: 10.1371/journal.pbio.3002119. eCollection 2023 May.
9
Phage Therapy Administration Route, Regimen, and Need for Supplementary Antibiotics in Patients with Chronic Suppurative Lung Disease.慢性化脓性肺病患者的噬菌体治疗给药途径、方案及补充抗生素的必要性
Phage (New Rochelle). 2023 Mar 1;4(1):4-10. doi: 10.1089/phage.2022.0036. Epub 2023 Mar 17.
10
Current Clinical Landscape and Global Potential of Bacteriophage Therapy.噬菌体疗法的当前临床现状和全球潜力。
Viruses. 2023 Apr 21;15(4):1020. doi: 10.3390/v15041020.